Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TELO
stocks logo

TELO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Telomir Pharmaceuticals Inc (TELO.O) is -4.69, compared to its 5-year average forward P/E of -5.88. For a more detailed relative valuation and DCF analysis to assess Telomir Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.88
Current PE
-4.69
Overvalued PE
1.44
Undervalued PE
-13.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4794.85
Current PS
0.00
Overvalued PS
38485.77
Undervalued PS
-28896.08
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TELO News & Events

Events Timeline

(ET)
2025-11-25
08:14:02
Telomir Pharmaceuticals Reveals Latest Preclinical Findings on Telomir-1
select
2025-11-21 (ET)
2025-11-21
07:32:56
Telomir Pharmaceuticals Reveals In Vitro Findings for Telomir-1
select
2025-11-12 (ET)
2025-11-12
08:31:10
Telomir Pharmaceuticals Reveals New Preclinical Findings on Telomir-1
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
10-10NASDAQ.COM
Friday's Underperformers: Pharmaceutical, Oil, and Gas Exploration & Production Shares

  • Market Performance: Oil and gas exploration and production shares are down approximately 1.6%, with Venture Global experiencing a significant drop of about 19.6% and Amplify Energy down by about 5.5%.

  • Sector Laggards: The decline in oil and gas stocks is highlighted as part of the broader market trends, alongside other sectors such as pharmaceuticals.

[object Object]
Preview
4.5
10-07Benzinga
Stock Market Update: Dow Jones and Nasdaq Futures Decline as Trade Deficit Data Release is Postponed Due to Shutdown—Trilogy Metals, AMD, and Applovin Under Scrutiny

  • U.S. Stock Market Update: U.S. stock futures declined following a mixed performance on Monday, with major indices showing slight decreases. The market is influenced by a deal between Advanced Micro Devices and OpenAI, which boosted AI-related stocks.

  • Government Shutdown Impact: The ongoing government shutdown has delayed the release of U.S. trade deficit data, with President Trump indicating a willingness to collaborate with Democrats on healthcare only after the government reopens.

  • Key Stock Movements: Trilogy Metals surged 180.38% after a White House investment announcement, while Applovin fell 2.56% amid an SEC investigation. Advanced Micro Devices rose 2.57% due to its deal with OpenAI, and Telomir Pharmaceuticals jumped 30.99% following positive study results.

  • Economic Outlook: Analysts predict a strong earnings season for Q3 2025, with expectations of low-teens earnings growth for the S&P 500, driven by AI investments and a resilient economy, despite potential tariff pressures.

[object Object]
Preview
2.0
10-07NASDAQ.COM
TELO, PCSA, RVPH, NMTC, BRTX Experience After-Hours Trading Surge Amid Limited News and Specific Updates

  • Biotech Stock Gains: Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX experienced significant after-hours gains driven by speculative trading and company updates, despite the absence of new disclosures.

  • Telomir Pharmaceuticals (TELO): TELO shares surged 43% after-hours, attributed to renewed interest in its in vitro data showcasing Telomir-1's unique targeting capabilities in cancer therapies.

  • Processa Pharmaceuticals (PCSA): PCSA shares rose 32.6% in after-hours trading, continuing a rally from the regular session, with no recent official news or updates from the company.

  • NeuroOne Medical Technologies (NMTC): NMTC shares increased 9.5% after announcing a 163% rise in preliminary product revenue for fiscal year 2025, alongside an upcoming virtual webinar, which sparked investor interest.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Telomir Pharmaceuticals Inc (TELO) stock price today?

The current price of TELO is 1.36 USD — it has increased 3.03 % in the last trading day.

arrow icon

What is Telomir Pharmaceuticals Inc (TELO)'s business?

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

arrow icon

What is the price predicton of TELO Stock?

Wall Street analysts forecast TELO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Telomir Pharmaceuticals Inc (TELO)'s revenue for the last quarter?

Telomir Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Telomir Pharmaceuticals Inc (TELO)'s earnings per share (EPS) for the last quarter?

Telomir Pharmaceuticals Inc. EPS for the last quarter amounts to -0.03 USD, decreased -85.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Telomir Pharmaceuticals Inc (TELO)'s fundamentals?

The market is revising No Change the revenue expectations for Telomir Pharmaceuticals, Inc. (TELO) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 9.68%.
arrow icon

How many employees does Telomir Pharmaceuticals Inc (TELO). have?

Telomir Pharmaceuticals Inc (TELO) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Telomir Pharmaceuticals Inc (TELO) market cap?

Today TELO has the market capitalization of 47.10M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free